Eyenovia, Inc. (NASDAQ:EYEN – Get Free Report) was the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 3,030,000 shares, a growth of 11.8% from the July 31st total of 2,710,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 2.0 days.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Eyenovia in a report on Tuesday, August 13th.
View Our Latest Analysis on Eyenovia
Insiders Place Their Bets
Institutional Trading of Eyenovia
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Leo Wealth LLC bought a new stake in Eyenovia during the 4th quarter worth about $34,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Eyenovia in the 4th quarter valued at about $84,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eyenovia during the 2nd quarter worth approximately $26,000. Ground Swell Capital LLC bought a new stake in shares of Eyenovia during the second quarter worth approximately $27,000. Finally, SkyView Investment Advisors LLC bought a new stake in shares of Eyenovia during the second quarter worth approximately $87,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.
Eyenovia Price Performance
NASDAQ EYEN traded down $0.03 during trading hours on Tuesday, reaching $0.52. 1,519,080 shares of the company’s stock were exchanged, compared to its average volume of 1,271,110. The firm has a fifty day moving average of $0.90 and a 200-day moving average of $0.98. The company has a current ratio of 0.46, a quick ratio of 0.27 and a debt-to-equity ratio of 3.72. Eyenovia has a one year low of $0.37 and a one year high of $2.57. The stock has a market cap of $33.60 million, a PE ratio of -0.73 and a beta of 1.77.
Eyenovia Company Profile
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
See Also
- Five stocks we like better than Eyenovia
- How to Calculate Stock Profit
- 3 Small Cap Stocks That Insiders Are Buying
- Health Care Stocks Explained: Why You Might Want to Invest
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- How Technical Indicators Can Help You Find Oversold Stocks
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.